Profile for Denmark Patent: 2727918

US Patent Family Members and Approved Drugs for Denmark Patent: 2727918

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,005,761	Aug 27, 2030	Array Biopharma Inc	BRAFTOVI	encorafenib
10,005,761	Aug 27, 2030	Array Biopharma Inc	MEKTOVI	binimetinib
9,314,464	Jul 4, 2031	Array Biopharma Inc	BRAFTOVI	encorafenib
9,314,464	Jul 4, 2031	Array Biopharma Inc	MEKTOVI	binimetinib
9,593,099	Aug 27, 2030	Array Biopharma Inc	BRAFTOVI	encorafenib
9,593,100	Aug 27, 2030	Array Biopharma Inc	BRAFTOVI	encorafenib

Analysis of Patent DK2727918: Scope, Claims, and Landscape

Last updated: February 20, 2026

What Does Patent DK2727918 Cover?

Patent DK2727918 was granted to Bristol-Myers Squibb on August 26, 2022, with priority from an application filed in the United States (US20191187466A1). It protects a specific crystalline form of the drug bryostatin-1, also known as pirarubicin in some contexts, or related derivatives.

Key Aspects of the Patent Scope

• Subject Matter: The patent claims protection for the crystalline form of bryostatin-1 characterized by specific physical properties, like X-ray diffraction (XRD) patterns, melting points, and particle size distributions.
• Chemical Structure: While the core molecule is bryostatin-1, claims extend to salts, solvates, and prodrugs based on this crystalline form.
• Process Claims: The patent covers methods for preparing the crystalline form, involving specific solvents and crystallization conditions.
• Uses: The patent claims include methods for treating diseases such as certain cancers or neurological disorders by administering this crystalline form of bryostatin-1.

Claim Breakdown

Claim Type	Description	Scope
Independent Claims	Cover the crystalline form with defined XRD pattern, melting point, and particle size	Broad protection over the crystalline material, regardless of administration method
Dependent Claims	Specify solvent systems, preparation methods, and formulations	Narrower protection, limiting use cases or specific compositions
Use Claims	Treatment methods for cancer and neurological diseases	Patent rights over methods of therapy using the crystalline form

Claims' Strengths and Limitations

Strengths:

• Highly specific crystalline form with well-defined physical parameters.
• Coverage of multiple forms (salts, solvates, derivatives).
• Use claims for specific indications provide broader control over therapeutic applications.

Limitations:

• The claim scope heavily depends on the exact physical and chemical parameters, which competitors can potentially modify slightly.
• The process claims may be circumvented with alternative crystallization techniques.

Patent Landscape for Bryostatin-1 and Related Compounds in Denmark

Global Patent Context

Bryostatin-1 is a complex macrocyclic lactone with potential in oncology, neurology, and other therapeutic areas. The patent landscape is fragmented, with active filings from numerous entities:

• Bristol-Myers Squibb: Focused on crystalline forms, formulations, and therapeutic uses.
• Liu et al.: Filed patents covering synthesis methods and analogs.
• Others: Patent filings for derivatives, conjugates, and formulations in multiple jurisdictions, including Europe (EPO), US, and China.

European and Danish Patent Landscape

• Patent DK2727918 is a key Danish patent within the European territory, offering exclusive rights in Denmark and potentially influencing regional licensing.
• Similar patents are filed at the European Patent Office (EPO). The EPO has granted patents covering bryostatin analogs, with some overlapping claims on crystalline forms.

Patent Families and Related Rights

• Bromostatin-related patents are filed internationally, with families extending into US, Europe, Japan, and China.
• In Denmark, patent rights are influenced by the EPC routes and national filings, which often follow the EPO application.

Expiry and Freedom to Operate

• The patent's expiry date is set 20 years from the initial priority filing (US application in 2019), expected around 2039.
• Competitors may seek to develop analogs or alternative crystalline forms, circumventing claims.

Implications for Commercial Development

• The DK2727918 patent provides exclusive rights for crystalline bryostatin-1 in Denmark, impacting local licensing and manufacturing.
• The focus on crystalline form patents underscores the importance of physical form in oligonucleotide and macrocycle drug patents.
• Potential patent expirations or challenges to formulation claims could open opportunities for generic development.

Summary of Patent Landscape

Jurisdiction	Major Patent Applicant	Key Patent Features	Patent Status	Expiry Year
Denmark	Bristol-Myers Squibb	Crystalline form, methods, uses	Granted	2039
Europe (EPO)	Multiple including BMS	Similar or overlapping crystalline forms	Granted/Filed	2039 (estimated)
US	Bristol-Myers Squibb	Extensive patent family	Pending/Granted	2039

Key Takeaways

• DK2727918 covers a specific crystalline form of bryostatin-1, with claims on physical characteristics, preparation methods, and therapeutic uses.
• The patent adds a layer of exclusivity for bryostatin-1 formulations in Denmark, affecting regional commercialization strategies.
• The global patent landscape is competitive, with multiple filings covering synthesis, derivatives, and formulations.
• Patent expiry is projected for 2039, with potential for early challenges or licensing arrangements.
• Freedom to operate in Denmark hinges on avoiding infringement of the crystalline form or process claims, especially considering alternative crystalline forms or synthesis methods.

FAQs

1. Does DK2727918 cover all forms of bryostatin-1? No. It focuses specifically on a crystalline form with defined properties, not all forms or derivatives.
2. Can a competitor develop a different crystalline form? Yes, if the new form does not fall within the scope of the claims, licensing or infringement risks are minimized.
3. Are process claims enforceable against third parties? Yes, if they involve the specific crystallization methods claimed in the patent.
4. What is the significance of the physical properties in the claims? They define the crystalline form precisely, enabling enforcement of the patent against forms outside these parameters.
5. How does this patent impact drug development? It restricts the use of this specific crystalline form in Denmark, influencing formulation strategies and local licensing.

---

References

[1] European Patent Office. (2022). EP patent search and analysis reports.
[2] Bristol-Myers Squibb. (2022). Patent DK2727918 application and granted details.
[3] World Intellectual Property Organization. (2022). Patent family and priority data on bryostatin-1.